SMCs With LVH Compared to HCM

N/AActive Not RecruitingNCT07006974

China National Center for Cardiovascular Diseases165 enrolled

Overview

The goal of this cohort study is to investigate the clinical characteristics of SMCs and to explore the difference in cardiovascular outcomes in comparison to age-, sex-, and admission year-matched HCM patients. The main question it aims to answer is: * Do patients with SMCs have higher rates of cardiac outcomes? * What risk factors do SMCs patients experience a poor prognosis?

Study Type

OBSERVATIONAL

Enrollment

165

Conditions

Syndromic and Metabolic Cardiomyopathy Cardiomyopathies

Interventions

SMCsOTHER

patients with SMCs

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * patients who were diagnosed SMCs or HCM. Gene testing and muscle biopsy were used to confirm the diagnosis of SMCs. The diagnose of HCM was according to the 2024 ESC Guidelines of HCM but without evidence of SMCs. * complete baseline data * accessible follow-up data Exclusion Criteria: * incomplete baseine data

Locations (1)

Fuwai Hospital, Chinese Academy of Medical Sciences

Beijing, China

Outcomes

Primary Outcomes

primary outcome

a composite of all-cause death, hospitalization for heart failure, myocardial infarction, ischemia or hemorrhagic stroke (excluding transient ischemic attack), other thrombotic events, and modified International Society on Thrombosis and Haemostasis crit

Time frame: 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.